Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Enasidenib Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Enasidenib Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Industry: Pharma & Healthcare

Published Date: 2025-09-06

Pages: 70 Pages

Report ld: 5029616

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Enasidenib Market Size(US$)

CAGR 2025-2031

7.1%

Market Size,2031

USD 142

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 94.4 million

Market Forecast in 2031(Value)

US$ 142 million

CAGR

7.1%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Enasidenib market size was US$ 88.7 million in 2024 and is forecast to a readjusted size of US$ 142 million by 2031 with a CAGR of 7.1% during the forecast period 2025-2031.

By 2025, the evolving U.S. tariff policy is poised to inject considerable uncertainty into the global economic landscape. This report delves into the latest U.S. tariff measures and the corresponding policy responses across the globe, evaluating their impacts on Enasidenib market competitiveness, regional economic performance, and supply chain configurations.

Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test

Enasidenib is a targeted therapy used to treat relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. Its efficacy in inhibiting the mutated IDH2 enzyme and inducing remission has driven market growth. The limited treatment options for this specific subset of AML contribute to its niche status. However, challenges include potential side effects and the need for genetic testing to identify eligible patients. The market competition is relatively small, as Enasidenib remains a targeted therapy for a specific AML subgroup. Despite challenges, the Enasidenib market offers potential for growth as healthcare providers seek effective treatments for patients with IDH2-mutated AML. Continued research and clinical advancements can further drive market expansion.

The global Enasidenib market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.

MARKET SEGMENTATION

By Company

Bristol Myers Squibb

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

50mg
100mg

Segment by Application

Hospital
Pharmacy

biaoTi CHAPTER OUTLINE

Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).

Chapter 2: Quantitative analysis of Enasidenib market size and growth potential at global, regional, and country levels.

Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).

Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., 100mg in China).

Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Pharmacy in India).

Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.

Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.

Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.

Chapter 9: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:

- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).

- Product Portfolio Optimization: Align offerings with regional preferences (e.g., 50mg dominance in Europe vs. 100mg demand in MEA).

- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Enasidenib Product Scope

1.2 Enasidenib by Type

1.2.1 Global Enasidenib Sales by Type (2020 & 2024 & 2031)

1.2.2 50mg

1.2.3 100mg

1.3 Enasidenib by Application

1.3.1 Global Enasidenib Sales Comparison by Application (2020 & 2024 & 2031)

1.3.2 Hospital

1.3.3 Pharmacy

1.4 Global Enasidenib Market Estimates and Forecasts (2020-2031)

1.4.1 Global Enasidenib Market Size in Value Growth Rate (2020-2031)

1.4.2 Global Enasidenib Market Size in Volume Growth Rate (2020-2031)

1.4.3 Global Enasidenib Price Trends (2020-2031)

1.5 Assumptions and Limitations

2 Market Size and Prospective by Region

2.1 Global Enasidenib Market Size by Region: 2020 VS 2024 VS 2031

2.2 Global Enasidenib Retrospective Market Scenario by Region (2020-2025)

2.2.1 Global Enasidenib Sales Market Share by Region (2020-2025)

2.2.2 Global Enasidenib Revenue Market Share by Region (2020-2025)

2.3 Global Enasidenib Market Estimates and Forecasts by Region (2026-2031)

2.3.1 Global Enasidenib Sales Estimates and Forecasts by Region (2026-2031)

2.3.2 Global Enasidenib Revenue Forecast by Region (2026-2031)

2.4 Major Region and Emerging Market Analysis

2.4.1 North America Enasidenib Market Size and Prospective (2020-2031)

3 Global Market Size by Type

3.1 Global Enasidenib Historic Market Review by Type (2020-2025)

3.1.1 Global Enasidenib Sales by Type (2020-2025)

3.1.2 Global Enasidenib Revenue by Type (2020-2025)

3.1.3 Global Enasidenib Price by Type (2020-2025)

3.2 Global Enasidenib Market Estimates and Forecasts by Type (2026-2031)

3.2.1 Global Enasidenib Sales Forecast by Type (2026-2031)

3.2.2 Global Enasidenib Revenue Forecast by Type (2026-2031)

3.2.3 Global Enasidenib Price Forecast by Type (2026-2031)

3.3 Different Types Enasidenib Representative Players

4 Global Market Size by Application

4.1 Global Enasidenib Historic Market Review by Application (2020-2025)

4.1.1 Global Enasidenib Sales by Application (2020-2025)

4.1.2 Global Enasidenib Revenue by Application (2020-2025)

4.1.3 Global Enasidenib Price by Application (2020-2025)

4.2 Global Enasidenib Market Estimates and Forecasts by Application (2026-2031)

4.2.1 Global Enasidenib Sales Forecast by Application (2026-2031)

4.2.2 Global Enasidenib Revenue Forecast by Application (2026-2031)

4.2.3 Global Enasidenib Price Forecast by Application (2026-2031)

4.3 New Sources of Growth in Enasidenib Application

5 Competition Landscape by Players

5.1 Global Enasidenib Sales by Players (2020-2025)

5.2 Global Top Enasidenib Players by Revenue (2020-2025)

5.3 Global Enasidenib Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enasidenib as of 2024)

5.4 Global Enasidenib Average Price by Company (2020-2025)

5.5 Global Key Manufacturers of Enasidenib, Manufacturing Sites & Headquarters

5.6 Global Key Manufacturers of Enasidenib, Product Type & Application

5.7 Global Key Manufacturers of Enasidenib, Date of Enter into This Industry

5.8 Manufacturers Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America Enasidenib Sales by Company

6.1.1.1 North America Enasidenib Sales by Company (2020-2025)

6.1.1.2 North America Enasidenib Revenue by Company (2020-2025)

6.1.2 North America Enasidenib Sales Breakdown by Type (2020-2025)

6.1.3 North America Enasidenib Sales Breakdown by Application (2020-2025)

6.1.4 North America Enasidenib Major Customer

6.1.5 North America Market Trend and Opportunities

7 Company Profiles and Key Figures

7.1 Bristol Myers Squibb

7.1.1 Bristol Myers Squibb Company Information

7.1.2 Bristol Myers Squibb Business Overview

7.1.3 Bristol Myers Squibb Enasidenib Sales, Revenue and Gross Margin (2020-2025)

7.1.4 Bristol Myers Squibb Enasidenib Products Offered

7.1.5 Bristol Myers Squibb Recent Development

8 Enasidenib Manufacturing Cost Analysis

8.1 Enasidenib Key Raw Materials Analysis

8.1.1 Key Raw Materials

8.1.2 Key Suppliers of Raw Materials

8.2 Proportion of Manufacturing Cost Structure

8.3 Manufacturing Process Analysis of Enasidenib

8.4 Enasidenib Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers

9.1 Marketing Channel

9.2 Enasidenib Distributors List

9.3 Enasidenib Customers

10 Enasidenib Market Dynamics

10.1 Enasidenib Industry Trends

10.2 Enasidenib Market Drivers

10.3 Enasidenib Market Challenges

10.4 Enasidenib Market Restraints

11 Research Findings and Conclusion

12 Appendix

12.1 Research Methodology

12.1.1 Methodology/Research Approach

12.1.1.1 Research Programs/Design

12.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

12.1.2 Data Source

12.1.2.1 Secondary Sources

12.1.2.2 Primary Sources

12.2 Author Details

12.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Enasidenib Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)

Table 2. Global Enasidenib Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)

Table 3. Global Market Enasidenib Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global Enasidenib Sales (Units) by Region (2020-2025)

Table 5. Global Enasidenib Sales Market Share by Region (2020-2025)

Table 6. Global Enasidenib Revenue (US$ Million) Market Share by Region (2020-2025)

Table 7. Global Enasidenib Revenue Share by Region (2020-2025)

Table 8. Global Enasidenib Sales (Units) Forecast by Region (2026-2031)

Table 9. Global Enasidenib Sales Market Share Forecast by Region (2026-2031)

Table 10. Global Enasidenib Revenue (US$ Million) Forecast by Region (2026-2031)

Table 11. Global Enasidenib Revenue Share Forecast by Region (2026-2031)

Table 12. Global Enasidenib Sales by Type (Units) & (2020-2025)

Table 13. Global Enasidenib Sales Share by Type (2020-2025)

Table 14. Global Enasidenib Revenue by Type (US$ Million) & (2020-2025)

Table 15. Global Enasidenib Price by Type (USD/Unit) & (2020-2025)

Table 16. Global Enasidenib Sales by Type (Units) & (2026-2031)

Table 17. Global Enasidenib Revenue by Type (US$ Million) & (2026-2031)

Table 18. Global Enasidenib Price by Type (USD/Unit) & (2026-2031)

Table 19. Representative Players of Each Type

Table 20. Global Enasidenib Sales by Application (Units) & (2020-2025)

Table 21. Global Enasidenib Sales Share by Application (2020-2025)

Table 22. Global Enasidenib Revenue by Application (US$ Million) & (2020-2025)

Table 23. Global Enasidenib Price by Application (USD/Unit) & (2020-2025)

Table 24. Global Enasidenib Sales by Application (Units) & (2026-2031)

Table 25. Global Enasidenib Revenue Market Share by Application (US$ Million) & (2026-2031)

Table 26. Global Enasidenib Price by Application (USD/Unit) & (2026-2031)

Table 27. New Sources of Growth in Enasidenib Application

Table 28. Global Enasidenib Sales by Company (Units) & (2020-2025)

Table 29. Global Enasidenib Sales Share by Company (2020-2025)

Table 30. Global Enasidenib Revenue by Company (US$ Million) & (2020-2025)

Table 31. Global Enasidenib Revenue Share by Company (2020-2025)

Table 32. Global Enasidenib by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enasidenib as of 2024)

Table 33. Global Market Enasidenib Average Price by Company (USD/Unit) & (2020-2025)

Table 34. Global Key Manufacturers of Enasidenib, Manufacturing Sites & Headquarters

Table 35. Global Key Manufacturers of Enasidenib, Product Type & Application

Table 36. Global Key Manufacturers of Enasidenib, Date of Enter into This Industry

Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 38. North America Enasidenib Sales by Company (2020-2025) & (Units)

Table 39. North America Enasidenib Sales Market Share by Company (2020-2025)

Table 40. North America Enasidenib Revenue by Company (2020-2025) & (US$ Million)

Table 41. North America Enasidenib Revenue Market Share by Company (2020-2025)

Table 42. North America Enasidenib Sales by Type (2020-2025) & (Units)

Table 43. North America Enasidenib Sales Market Share by Type (2020-2025)

Table 44. North America Enasidenib Sales by Application (2020-2025) & (Units)

Table 45. North America Enasidenib Sales Market Share by Application (2020-2025)

Table 46. Bristol Myers Squibb Company Information

Table 47. Bristol Myers Squibb Description and Business Overview

Table 48. Bristol Myers Squibb Enasidenib Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 49. Bristol Myers Squibb Enasidenib Product

Table 50. Bristol Myers Squibb Recent Development

Table 51. Production Base and Market Concentration Rate of Raw Material

Table 52. Key Suppliers of Raw Materials

Table 53. Enasidenib Distributors List

Table 54. Enasidenib Customers List

Table 55. Enasidenib Market Trends

Table 56. Enasidenib Market Drivers

Table 57. Enasidenib Market Challenges

Table 58. Enasidenib Market Restraints

Table 59. Research Programs/Design for This Report

Table 60. Key Data Information from Secondary Sources

Table 61. Key Data Information from Primary Sources

List of Figures

Figure 1. Enasidenib Product Picture

Figure 2. Global Enasidenib Sales (US$ Million) by Type (2020 & 2024 & 2031)

Figure 3. Global Enasidenib Sales Market Share by Type in 2024 & 2031

Figure 4. 50mg Product Picture

Figure 5. 100mg Product Picture

Figure 6. Global Enasidenib Sales (US$ Million) by Application (2020 & 2024 & 2031)

Figure 7. Global Enasidenib Sales Market Share by Application in 2024 & 2031

Figure 8. Hospital Examples

Figure 9. Pharmacy Examples

Figure 10. Global Enasidenib Sales, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Enasidenib Sales Growth Rate (2020-2031) & (US$ Million)

Figure 12. Global Enasidenib Sales (Units) Growth Rate (2020-2031)

Figure 13. Global Enasidenib Price Trends Growth Rate (2020-2031) & (USD/Unit)

Figure 14. Enasidenib Report Years Considered

Figure 15. Global Market Enasidenib Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Figure 16. Global Enasidenib Revenue Market Share by Region: 2020 VS 2024

Figure 17. North America Enasidenib Revenue (US$ Million) Growth Rate (2020-2031)

Figure 18. North America Enasidenib Sales (Units) Growth Rate (2020-2031)

Figure 19. Global Enasidenib Revenue Share by Type (2020-2025)

Figure 20. Global Enasidenib Sales Share by Type (2026-2031)

Figure 21. Global Enasidenib Revenue Share by Type (2026-2031)

Figure 22. Global Enasidenib Revenue Share by Application (2020-2025)

Figure 23. Global Enasidenib Revenue Growth Rate by Application in 2020 & 2024

Figure 24. Global Enasidenib Sales Share by Application (2026-2031)

Figure 25. Global Enasidenib Revenue Share by Application (2026-2031)

Figure 26. Global Enasidenib Sales Share by Company (2024)

Figure 27. Global Enasidenib Revenue Share by Company (2024)

Figure 28. Global 5 Largest Enasidenib Players Market Share by Revenue in Enasidenib: 2020 & 2024

Figure 29. Enasidenib Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 30. Manufacturing Cost Structure of Enasidenib

Figure 31. Manufacturing Process Analysis of Enasidenib

Figure 32. Enasidenib Industrial Chain

Figure 33. Channels of Distribution (Direct Vs Distribution)

Figure 34. Distributors Profiles

Figure 35. Bottom-up and Top-down Approaches for This Report

Figure 36. Data Triangulation

Figure 37. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which region is expected to have the highest market share? zhanKai

For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 7.1% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.

What is the annual compound growth rate of the global Enasidenib market size from 2025 to 2031? shouQi

Which companies rank high in the global Enasidenib market? shouQi

What was the global market size of Enasidenib in 2025? shouQi

What was the global market size of Enasidenib in 2031? shouQi

Related Reports

Enasidenib- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Enasidenib was estimated to be worth US$ 94.4 million in 2025 and is projected to reach US$ 152 million, growing at a CAGR of 7.1% from 2026 to 2032.
Published Date: 2026-07-14
Pages: 125
USD 3950.00
(Single User License)
Global Enasidenib Market Research Report 2026
The global Enasidenib market was valued at US$ 94.4 million in 2025 and is anticipated to reach US$ 152 million by 2032, at a CAGR of 7.1% from 2026 to 2032.
Published Date: 2026-04-27
Pages: 106
USD 2900.00
(Single User License)
Enasidenib- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Enasidenib was estimated to be worth US$ 88.7 million in 2024 and is forecast to a readjusted size of US$ 142 million by 2031 with a CAGR of 7.1% during the forecast period 2025-2031.
Published Date: 2025-02-25
Pages: 87
USD 3950.00
(Single User License)
Global Enasidenib Market Research Report 2025
The global market for Enasidenib was valued at US$ 88.7 million in the year 2024 and is projected to reach a revised size of US$ 142 million by 2031, growing at a CAGR of 7.1% during the forecast period.
Published Date: 2025-02-25
Pages: 74
USD 2900.00
(Single User License)
Global Enasidenib Market Insights, Forecast to 2030
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
Published Date: 2024-04-25
Pages: 72
USD 4900.00
(Single User License)
Enasidenib - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
Published Date: 2024-01-24
Pages: 89
USD 3950.00
(Single User License)
Global Enasidenib Market Research Report 2024
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
Published Date: 2024-01-05
Pages: 67
USD 2900.00
(Single User License)

Enasidenib- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Enasidenib was estimated to be worth US$ 94.4 million in 2025 and is projected to reach US$ 152 million, growing at a CAGR of 7.1% from 2026 to 2032.
Published: 2026-07-14
Pages: 125
USD 3950.00 (Single User License)
Global Enasidenib Market Research Report 2026
The global Enasidenib market was valued at US$ 94.4 million in 2025 and is anticipated to reach US$ 152 million by 2032, at a CAGR of 7.1% from 2026 to 2032.
Published: 2026-04-27
Pages: 106
USD 2900.00 (Single User License)
Enasidenib- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Enasidenib was estimated to be worth US$ 88.7 million in 2024 and is forecast to a readjusted size of US$ 142 million by 2031 with a CAGR of 7.1% during the forecast period 2025-2031.
Published: 2025-02-25
Pages: 87
USD 3950.00 (Single User License)
Global Enasidenib Market Research Report 2025
The global market for Enasidenib was valued at US$ 88.7 million in the year 2024 and is projected to reach a revised size of US$ 142 million by 2031, growing at a CAGR of 7.1% during the forecast period.
Published: 2025-02-25
Pages: 74
USD 2900.00 (Single User License)
Global Enasidenib Market Insights, Forecast to 2030
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
Published: 2024-04-25
Pages: 72
USD 4900.00 (Single User License)
Enasidenib - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
Published: 2024-01-24
Pages: 89
USD 3950.00 (Single User License)
Global Enasidenib Market Research Report 2024
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
Published: 2024-01-05
Pages: 67
USD 2900.00 (Single User License)